GMAB: רווח נקי למניה ב-12 החודשים האחרונים genmab.com
Genmab A/S monetizes exclusive patents through high royalties from blockbuster sales. The change in rolling net income per share clearly confirms this strategy, with the latest parameter standing at 1.17. Growth is driven by alliances with pharma behemoths to accelerate therapy, while indirect pricing power shifts primary financial risks onto partners utilizing the company's unique antibodies.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_GMAB_-_Genmab-AS_-_Earnings-per-share-for-the-last-four-quarters "Genmab US - רווח נקי למניה (EPS TTM) GMAB (תקופה 04.07.2022 - 10.11.2026) | 👁️GURU.Markets👁️")
פילוחים אנליטיים של חברת Genmab A/S
To objectively assess the operational efficiency of Genmab A/S, it is essential for investors to track the actual yield of each security. Fundamental net income per share TTM aggregates net income over the year and divides it by the number of shares, reflecting how successfully scientific freedom and oncological research are converted into financial results that determine the long-term value of the business.
